2020
Stem Cell Therapy for Thromboangiitis Obliterans (Buerger’s Disease)
Dash B, Peyvandi H, Duan K, Richardson E, Ndon S, Gabrick K, Faz A, Persing J, Dardik A, Hsia H. Stem Cell Therapy for Thromboangiitis Obliterans (Buerger’s Disease). Processes 2020, 8: 1408. DOI: 10.3390/pr8111408.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsThromboangiitis obliteransYoung male smokersBuerger's diseaseImmunomodulatory approachesMale smokersSurgical bypassPathological findingsTreatment modalitiesVascular diseaseDefinitive cureLower extremitiesMedium arteriesLesion treatmentTherapeutic modalitiesTAO treatmentTherapeutic angiogenesisCell therapyDiseaseObliteransStem cellsCurrent knowledgeModalitiesTreatmentPotential optionVasculitis
2018
Increased mortality in octogenarians treated for lifestyle limiting claudication
Erben Y, Mena‐Hurtado C, Miller S, Jean R, Sumpio BJ, Velasquez CA, Mojibian H, Aruny J, Dardik A, Sumpio B. Increased mortality in octogenarians treated for lifestyle limiting claudication. Catheterization And Cardiovascular Interventions 2018, 91: 1331-1338. PMID: 29405592, DOI: 10.1002/ccd.27523.Peer-Reviewed Original ResearchMeSH KeywordsAge FactorsAgedAged, 80 and overComorbidityDatabases, FactualEndovascular ProceduresFemaleHealth StatusHumansIntermittent ClaudicationLength of StayMaleMiddle AgedPeripheral Arterial DiseaseRetrospective StudiesRisk FactorsTime FactorsTreatment OutcomeUnited StatesVascular Surgical ProceduresConceptsCharlson Comorbidity IndexOpen surgeryTreatment modalitiesHigher Charlson comorbidity indexMean Charlson Comorbidity IndexYounger cohortsInfectious wound complicationsInfra-inguinal interventionsAcute kidney injuryPeripheral arterial diseasePeripheral artery diseaseCongestive heart failureNationwide Inpatient SampleBinary logistic regression analysisLogistic regression analysisSkilled nursing facilitiesTreatment of LLCHospital mortalityComorbidity indexExercise therapyHospital stayKidney injuryOverall morbidityWound complicationsLonger LOS